尽管Biohaven制药公司（BHVN）针对抑郁症治疗的BHV-7000二期研究未达到主要终点，雷蒙德·詹姆斯分析师指出，该公司仍蕴藏巨大潜力。分析师维持对该股的"强力买入"评级，因其更关注Biohaven将BHV-7000应用于癫痫治疗的开发计划。
这款药物在癫痫治疗领域展现卓越前景，其安全性数据可能优于竞争药物阿泽塔克纳。分析师强调，Biohaven计划于2026年1月公布最新数据，并在上半年完成癫痫适应症的首次关键数据解读，此举有望显著提升短期估值。
（本文根据市场讨论整理，不构成投资建议）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.